scholarly journals Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1cin New-Onset Type 1 Diabetes

Diabetes Care ◽  
2018 ◽  
Vol 41 (9) ◽  
pp. 1917-1925 ◽  
Author(s):  
Michael J. Haller ◽  
Desmond A. Schatz ◽  
Jay S. Skyler ◽  
Jeffrey P. Krischer ◽  
Brian N. Bundy ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Low Dose ◽  
Cell Function ◽  
Β Cell ◽  
Onset Type ◽  
Β Cell Function ◽  
New Onset

Association of T-cell reactivity with β-cell function in recent onset type 1 diabetes patients

2010 ◽  
Vol 34 (2) ◽  
pp. 127-135 ◽  
Author(s):  
Christian Pfleger ◽  
Guido Meierhoff ◽  
Hubert Kolb ◽  
Nanette C. Schloot
Keyword(s):  
Type 1 Diabetes ◽  
T Cell ◽  
Cell Function ◽  
Β Cell ◽  
Cell Reactivity ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function ◽  
T Cell Reactivity

β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

The Lancet ◽  
2001 ◽  
Vol 358 (9295) ◽  
pp. 1749-1753 ◽  
Author(s):  
Itamar Raz ◽  
Dana Elias ◽  
Ann Avron ◽  
Merana Tamir ◽  
Muriel Metzger ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Cell Function ◽  
Phase Ii Trial ◽  
Β Cell ◽  
Double Blind ◽  
Β Cell Function ◽  
New Onset

Effect of camel milk on residual β-cell function in recent onset type 1 diabetes

2007 ◽  
Vol 77 (3) ◽  
pp. 494-495 ◽  
Author(s):  
Rajendra P. Agrawal ◽  
Sanjay Saran ◽  
Poornima Sharma ◽  
Rajendra P. Gupta ◽  
Dhanpat K. Kochar ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Camel Milk ◽  
Β Cell ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function

The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI)

2006 ◽  
Vol 23 (8) ◽  
pp. 920-923 ◽  
Author(s):  
D. Pitocco ◽  
A. Crino ◽  
E. Di Stasio ◽  
S. Manfrini ◽  
C. Guglielmi ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Pancreatic Β Cell ◽  
Β Cell ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function

scholarly journals Updates on Immune Therapies in Type 1 Diabetes

2016 ◽  
Vol 12 (2) ◽  
pp. 89 ◽  
Author(s):  
Bimota Nambam ◽  
◽  
Michael J Haller ◽  
Keyword(s):  
Clinical Trials ◽  
Type 1 Diabetes ◽  
Cell Function ◽  
Β Cell ◽  
Immune Therapies ◽  
Β Cell Function ◽  
Potential Benefits ◽  
New Onset

Multiple clinical trials investigating the efficacy and safety of immunotherapeutic interventions in new onset type 1 diabetes (T1D) have failed to yield long term clinical benefit. Lack of efficacy has frequently been attributed to an incomplete understanding of the pathways involved in T1D and the use of single immunotherapeutic agents. Recent mechanistic studies have improved our knowledge of the complex etiopathogenesis of T1D. This in turn has provided the framework for new and ongoing clinical trials in new onset T1D patients and at-risk subjects. Focus has also shifted towards the potential benefits of synergistic combinatorial approaches, both in terms of efficacy and the potential for reduced side effects. These efforts seek to develop intervention strategies that will preserve β-cell function, and ultimately prevent and reverse clinical disease.

scholarly journals Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

Diabetes Care ◽  
2015 ◽  
pp. dc141575 ◽  
Author(s):  
Simke Demeester ◽  
Bart Keymeulen ◽  
Leonard Kaufman ◽  
Annelien Van Dalem ◽  
Eric V. Balti ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Insulin Autoantibodies ◽  
Β Cell ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function

scholarly journals 100 years post insulin: immunotherapy as the next frontier in Type 1 Diabetes

2021 ◽  
Author(s):  
James A Pearson ◽  
Eoin F McKinney ◽  
Lucy S K Walker
Keyword(s):  
Type 1 Diabetes ◽  
Autoimmune Disease ◽  
Turning Point ◽  
Cell Function ◽  
Β Cells ◽  
Β Cell ◽  
Β Cell Function ◽  
Selection Of ◽  
New Onset

Abstract Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.

Sign in / Sign up

Export Citation Format

Share Document